BioCardia, Inc.

BioCardia is headquartered in the United States and its core commercial and clinical activity is centered there. The company’s CardiAMP heart failure trial enrolled patients at 18 centers in the United States and Canada, showing that North America is the main development footprint. BioCardia also has a meaningful Japan pathway, where it has held a positive preliminary consultation with PMDA and is preparing for a formal clinical consultation that could support market entry. Outside the U.S., the company has international partnering exposure through CART-Tech, B.V. in the Netherlands and broader worldwide rights for biotherapeutic delivery. Because the company is still pre-scale, geography matters mainly through regulatory approvals, trial execution, and partner commercialization rather than through a large installed sales base.

BioCardia faces substantial going-concern and financing risk because management has disclosed that existing cash is not sufficient to fund operations beyond the near term. The company also depends on clinical trial outcomes and regulatory acceptance for CardiAMP and other candidates, so setbacks in efficacy, safety, or approval timing could materially delay commercialization. As a small-cap development-stage issuer, it is exposed to Nasdaq continued listing risk, and delisting would make capital raising and partner confidence more difficult. More broadly, the business depends on reimbursement, physician adoption, and competition from alternative heart failure and electrophysiology technologies, all of which can slow uptake even after regulatory clearance. Because much of the value is tied to a few programs, any failure in one program can have an outsized effect on the company.